According to Gram Research analysis, a pilot study found that children with myotonic dystrophy type 1 have significantly lower levels of a beneficial gut bacteria called Faecalibacterium compared to their healthy siblings, with affected children averaging 4.9% versus 9.1% in unaffected siblings. This early research suggests gut bacteria differences may contribute to the digestive and developmental problems common in myotonic dystrophy, though much larger studies are needed to confirm this finding and determine whether targeting this bacteria could become a treatment strategy.
A new pilot study looked at the gut bacteria of children with myotonic dystrophy type 1 (DM1), a genetic muscle disease that often causes digestive and brain development problems. Researchers compared the gut bacteria of 11 children and young adults with DM1 to their unaffected siblings. They found that kids with DM1 had significantly lower levels of a helpful bacteria called Faecalibacterium. While this is early research with a small group, the finding suggests that gut bacteria differences might help explain why children with DM1 often struggle with digestive issues and developmental challenges. This discovery could eventually lead to new treatments targeting these bacteria.
Key Statistics
A 2026 pilot study of 21 participants found that children with myotonic dystrophy type 1 had significantly lower levels of Faecalibacterium bacteria (4.9% average) compared to their unaffected siblings (9.1% average), suggesting gut bacteria differences may play a role in the disease.
In a within-family comparison study published in 2026, the reduction in Faecalibacterium bacteria in children with myotonic dystrophy type 1 was statistically significant (p=0.005), though the overall diversity of gut bacteria communities remained similar between affected and unaffected siblings.
A 2026 research article examining 11 children and one young adult with myotonic dystrophy type 1 found that reduced Faecalibacterium abundance, a key gut bacterium previously linked to gastrointestinal and neurodevelopmental disorders, may be relevant to symptoms frequently seen in DM1.
The Quick Take
- What they studied: Whether children with myotonic dystrophy type 1 have different gut bacteria compared to their healthy siblings, and if these differences might explain their digestive and developmental problems.
- Who participated: A small group of 11 children and one young adult with myotonic dystrophy type 1, plus 11 of their unaffected siblings. Researchers collected food records and stool samples to study their gut bacteria.
- Key finding: Children with myotonic dystrophy had about half the amount of a beneficial bacteria called Faecalibacterium (4.9%) compared to their healthy siblings (9.1%). This difference was statistically significant, meaning it’s unlikely to be due to chance.
- What it means for you: This early-stage research suggests gut bacteria may play a role in digestive and developmental problems seen in myotonic dystrophy. However, this is a very small pilot study, so much larger research is needed before doctors could use this information to develop new treatments. If you have a child with DM1, discuss any digestive concerns with your healthcare provider.
The Research Details
This was a pilot study, which means it was a small, exploratory project designed to test whether a bigger study would be worthwhile. The researchers recruited 11 children and one young adult with myotonic dystrophy type 1 and compared them to 11 of their unaffected siblings. By comparing siblings, the researchers could account for factors that run in families, like diet and lifestyle, which might affect gut bacteria. Participants kept food records for three days and provided stool samples. The researchers then used a genetic test called 16S rRNA sequencing to identify and count the different types of bacteria in each person’s gut.
This research approach is important because myotonic dystrophy is a rare genetic disease, making it hard to find large groups of patients for study. By comparing siblings who share the same home environment and diet, researchers could focus on differences caused by the disease itself rather than lifestyle factors. The within-family design is a smart way to control for confounding factors, which strengthens the reliability of the findings. However, the small sample size means results should be considered preliminary and exploratory.
This is a pilot study with only 21 total participants, which is quite small. The researchers used a solid research design by comparing siblings, which helps control for environmental factors. However, the statistical analysis was uncorrected for multiple testing, meaning some findings could be false positives by chance. The study was published in a peer-reviewed journal, which means other experts reviewed the work before publication. Readers should understand this is early-stage research meant to generate hypotheses for larger future studies, not definitive proof of cause and effect.
What the Results Show
The main finding was that children with myotonic dystrophy had significantly lower levels of the bacteria Faecalibacterium compared to their healthy siblings. Specifically, children with DM1 had an average of 4.9% of this bacteria in their gut, while their siblings had 9.1%, a difference that was statistically significant (p=0.005). This means the difference is unlikely to be due to random chance. Interestingly, the overall diversity and structure of gut bacteria communities were similar between the two groups. This suggests that the difference is specific to this one type of bacteria rather than a complete reshaping of the entire gut microbiome.
While the study focused primarily on Faecalibacterium, the researchers also examined overall microbial diversity and community structure. They found no significant differences in these broader measures between children with DM1 and their unaffected siblings. This suggests that the gut microbiome changes in DM1 may be subtle and specific to certain bacteria rather than dramatic overall shifts.
Faecalibacterium is known from previous research to be an important beneficial bacteria in the human gut. Lower levels of this bacteria have been reported in other conditions associated with DM1, including gastrointestinal disorders and neurodevelopmental problems. This finding aligns with existing knowledge about which bacteria are affected in related conditions, making it biologically plausible. However, this is the first study to specifically examine gut bacteria in children with myotonic dystrophy, so there is no direct prior research to compare against.
This study has several important limitations. First, it included only 21 people total, which is a very small sample size. Second, the statistical analysis was uncorrected for multiple testing, meaning some findings could be false positives. Third, this is a pilot study that cannot prove cause and effect, only that an association exists. Fourth, the study was cross-sectional, meaning it captured a single snapshot in time rather than following people over months or years. Finally, the researchers cannot determine whether the lower Faecalibacterium causes the digestive and developmental problems in DM1, or whether the disease causes the bacteria changes, or whether some other factor causes both.
The Bottom Line
This research is too preliminary to make specific recommendations for patients or families. The findings suggest that gut bacteria may play a role in myotonic dystrophy symptoms, but much larger studies are needed to confirm this. If you have a child with DM1 experiencing digestive issues, work with your healthcare team to manage symptoms. Do not make dietary changes or use probiotics specifically targeting Faecalibacterium based on this single pilot study, as there is insufficient evidence to support such interventions at this time.
This research is most relevant to families with children who have myotonic dystrophy type 1, particularly those experiencing digestive or developmental challenges. It may also interest researchers studying neuromuscular diseases and the gut microbiome. Healthcare providers treating DM1 patients should be aware of this emerging research direction. The general public should understand this as early-stage science that may eventually lead to new treatments, but not as actionable medical advice today.
This is preliminary research, so realistic expectations are that it will take several years before any potential treatments could be developed and tested. Larger confirmation studies would need to be conducted first, followed by mechanistic studies to understand how Faecalibacterium relates to DM1 symptoms. If a therapeutic approach is eventually developed, clinical trials would be needed before it could be offered to patients. Expect a timeline of 5 to 10 years or more before any clinical applications might emerge.
Frequently Asked Questions
What is myotonic dystrophy and why do kids with it have digestive problems?
Myotonic dystrophy type 1 is a genetic muscle disease affecting multiple body systems. Children with DM1 often experience digestive issues and developmental delays, but the exact reasons have been unclear. This new research suggests gut bacteria differences may contribute to these problems.
Should I give my child probiotics if they have myotonic dystrophy?
This pilot study is too preliminary to recommend specific probiotic treatments. While the findings are interesting, much larger research is needed before doctors could recommend targeting Faecalibacterium. Always discuss any supplements or dietary changes with your child’s healthcare provider first.
How does gut bacteria affect brain development and digestion?
The gut microbiome produces chemicals that influence digestion, immune function, and brain development through the gut-brain connection. Faecalibacterium specifically produces beneficial compounds called short-chain fatty acids that support gut and brain health. Lower levels may impair these protective functions.
Will this research lead to a cure for myotonic dystrophy?
This is early-stage research exploring one potential contributing factor to DM1 symptoms. Even if gut bacteria play a role, treating it would likely help manage symptoms rather than cure the underlying genetic disease. Multiple larger studies would be needed before any new treatments could be developed.
Why did researchers compare siblings instead of just studying kids with myotonic dystrophy?
Comparing siblings who share the same home, diet, and family genetics helps researchers isolate the effects of the disease itself. This design controls for environmental factors that might affect gut bacteria, making it easier to identify disease-specific changes in the microbiome.
Want to Apply This Research?
- For families with children who have myotonic dystrophy, track gastrointestinal symptoms daily using a simple scale (none, mild, moderate, severe) along with notes about diet, bowel movements, and overall comfort. Record this in a health tracking app to share patterns with your healthcare provider.
- While this research is too early to recommend specific interventions, families can use a health app to document which foods seem to trigger or improve digestive symptoms in their child with DM1. This personalized tracking may help identify dietary patterns worth discussing with a gastroenterologist or nutritionist.
- Set up monthly reviews in your health app to look for patterns in digestive symptoms, energy levels, and developmental milestones. Share these trends with your child’s healthcare team during regular appointments. As research on gut bacteria and DM1 advances, this baseline data could become valuable for future treatment decisions.
This article summarizes preliminary pilot research and should not be considered medical advice. Myotonic dystrophy type 1 is a serious genetic condition requiring ongoing care from qualified healthcare providers. Do not make changes to your child’s diet, supplements, or medical treatment based on this single pilot study. The findings are exploratory and require confirmation through larger research studies. Always consult with your child’s physician, neurologist, or gastroenterologist before making any health-related decisions. This research does not establish cause and effect, only an association between gut bacteria and DM1 in a very small sample.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.